Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V, Passos Coelho JL, Duhoux FP, Egle D, García-Sáenz JÁ, Penault-Llorca F, Selander K, Wildiers H, Zaman K, Laeis P, Lucerna M, Pierga JY.
Guarneri V, et al. Among authors: selander k.
Future Oncol. 2024 Apr 9. doi: 10.2217/fon-2024-0015. Online ahead of print.
Future Oncol. 2024.
PMID: 38592002
Free article.
Review.